<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00968032</url>
  </required_header>
  <id_info>
    <org_study_id>09k003</org_study_id>
    <nct_id>NCT00968032</nct_id>
  </id_info>
  <brief_title>Procedural Success and Safety of the Nit-Occlud® Patent Foramen Ovale (PFO) Closure Device and Its Application System</brief_title>
  <acronym>09k003</acronym>
  <official_title>Single-center Non-comparative, Prospective Interventional Clinical Investigation on the Procedural Success and Safety of the Nit-Occlud® PFO Closure Device and Its Application System.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>pfm medical ag</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MDT Medical Device Testing GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>pfm medical ag</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The foramen ovale is an opening in the interatrial septum. It results from an incomplete
      coverage of the ostium secundum. In 10 to 24% of the general population incomplete fibrosis
      of the interatrial septum is a clinical finding and is defined as a patent foramen ovale
      (PFO). The Nit-Occlud® PFO umbrella is a permanent implant for closing PFOs that is implanted
      in the PFO using minimally invasive catheter technology. The umbrella is made from Nitinol, a
      material with superelastic properties, which, in its relaxed state, has the form of a double
      umbrella. This is a single-center, non-comparative, prospective interventional clinical
      investigation involving 1 center in Germany to assess the effectiveness, safety and
      practicability of implantation of the Nit-Occlud PFO® Closure Device.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Successful Implantation.</measure>
    <time_frame>6 weeks ± 2 weeks</time_frame>
    <description>The implantation of the device under investigation in a single patient is defined as successful if delivery, placement and release of the device in a stable position is successful. The value will be compared to the number of patient enrolled.</description>
  </primary_outcome>
  <enrollment type="Actual">63</enrollment>
  <condition>Foramen Ovale, Patent</condition>
  <condition>Heart Catheterization</condition>
  <condition>Heart Septal Defects, Atrial</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nit-Occlud® PFO</intervention_name>
    <description>Transcatheter implantation of a PFO occluder (Nitinol double Umbrella)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of patent foramen ovale (PFO)

          1. Age between 18 and 65 years of both gender

          2. Ability to give written informed consent after being told the potential benefits and
             risks of entering the trial to understand the planned clinical study and able to
             participate in all follow-up procedures

          3. Signed informed consent

          4. Presenting with neurological symptoms and at least one of the following clinical
             circumstances:

               -  Diagnosis of cryptogenic stroke based on clinical neurological examination

               -  Diagnosis of a transient ischemic attack (TIA) based on clinical neurological
                  examination

          5. PFO defect with or without atrial septal aneurysm of a balloon stretched diameter less
             than 18 mm. PFO tunnel length less than 10 mm in TEE

          6. Mental and physical ability of patient to follow the protocol according to compliance
             to time schedule, treatment plan,completion of CRF pages and further study procedures.

        Exclusion Criteria:

          1. PFO dimensions exceeding Inclusion criterium 5)

          2. Active endocarditis

          3. Presence of an infectious disease

          4. Vascular anatomy unable to accommodate the appropriate-sized sheath for device
             introduction

          5. Current arrhythmia, or history of arrhythmia

          6. Prior cardiac surgery, including implantation of active and non-active cardiac device
             (coronary stent is allowed)

          7. Confinement to bed (because of higher potential for clot formation)

          8. Heart abnormality other than PFO

          9. Accessory atrial defects

         10. Participation in an investigational drug or device trial within 30 days prior to
             selection, or current inclusion in any other clinical trial or research project

         11. Known allergy to nickel

         12. Known allergy to contrast agents

         13. Cancerogenic disease or malignant tumor, or other severe disease

         14. Intracardiac mass or vegetation

         15. Thrombus at the intended site of implant or documented evidence of venous thrombus in
             the vessel to which access to the defect is gained

         16. Unable to tolerate Aspirin or Clopidogrel, and/or antibiotic prophylaxis for at least
             three months following the procedure

         17. Pregnant or breast feeding female patients

         18. Subjects who, in the opinion of the investigator, will be inappropriate for inclusion
             into this trial or will not comply with requirements of the study

         19. Subjects who are imprisoned (according to MPG § 20.3)

         20. Patients who are lawfully kept in an institution
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Horst Sievert, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardio-Vascular Centre, Sankt Kathrinen, Frankfurt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardio-Vascular Centre, Sankt Kathrinen</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2009</study_first_submitted>
  <study_first_submitted_qc>August 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2009</study_first_posted>
  <results_first_submitted>January 27, 2011</results_first_submitted>
  <results_first_submitted_qc>February 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 9, 2011</results_first_posted>
  <last_update_submitted>May 30, 2011</last_update_submitted>
  <last_update_submitted_qc>May 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Christof Schmeer head of quality assurance pfm group</name_title>
    <organization>pfm medical ag</organization>
  </responsible_party>
  <keyword>PFO</keyword>
  <keyword>Patent Foramen Ovale</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Septal Defects</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
    <mesh_term>Heart Septal Defects, Atrial</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period was set between June 2009 and July 2010 at a single medical clinic.</recruitment_details>
      <pre_assignment_details>No enrolled participants were excluded from the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nit-Occlud® PFO Implantation Group</title>
          <description>Patients suffering from PFO and suitable for closure of the defect with the Nit-Occlud® PFO Closure Device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61">1 patient not receiving investigational device due to failure in usage
1 patient denied latest FU</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nit-Occlud® PFO</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.7" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Successful Implantation.</title>
        <description>The implantation of the device under investigation in a single patient is defined as successful if delivery, placement and release of the device in a stable position is successful. The value will be compared to the number of patient enrolled.</description>
        <time_frame>6 weeks ± 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nit-Occlud® PFO</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Successful Implantation.</title>
          <description>The implantation of the device under investigation in a single patient is defined as successful if delivery, placement and release of the device in a stable position is successful. The value will be compared to the number of patient enrolled.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were observed for each patient during a 6 week FU period (6 weeks +- 2 weeks). Adverse events were judged by the relationship to the investigational device</time_frame>
      <desc>No AE led to discontinuation of the study. Causal relationship to the device was not ruled out in 19 AEs. Within these, for 15 AEs the relationship was recorded as unknown, 2 AEs were recorded as possibly related, and 2 AEs were recorded as related. All device related AEs were reported as of mild intensity.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nit-Occlud® PFO</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac General</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurology</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary/Upper respiratory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christof Schmeer</name_or_title>
      <organization>pfm medical ag</organization>
      <phone>+49 6873 9011 ext 41</phone>
      <email>christof.schmeer@pfmmedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

